BioAge raises $170M as obesity spotlight shifts to oral options, muscle preservers

BioAge Labs has reeled in the biotech in­dus­try’s largest pri­vate fi­nanc­ing round so far in 2024 as the Cal­i­for­nia start­up goes full throt­tle on the hottest ar­eas in obe­si­ty drug de­vel­op­ment: oral for­mu­la­tions and mus­cle preser­va­tion.

The biotech, which emerged as one of the an­ti-ag­ing play­ers in 2015, is mov­ing for­ward with aze­laprag, a drug it li­censed from Am­gen af­ter the phar­ma had at­tempt­ed de­vel­op­ing it for heart fail­ure. Its $170 mil­lion Se­ries D, dis­closed Tues­day morn­ing, is the 10th megaround (at least $100 mil­lion) of the year, per End­points News da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.